ARYLPYRAZOLYLPIPERAZINE OR ARYLPYRAZOLYLDIAZEPANE DERIVATIVE ACTING AS 5-HT7 RECEPTOR REGULATOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR TREATMENT OR PREVENTION OF CENTRAL NERVOUS SYSTEM DISORDER

The present invention relates to an arylpyrazolylpiperazine or arylpyrazolyldiazepane derivative represented by Structural Formula 1 and a pharmaceutically acceptable salt thereof. An arylpyrazolylpiperazine or arylpyrazolyldiazepane derivative and a pharmaceutically acceptable salt thereof accordin...

Full description

Saved in:
Bibliographic Details
Main Authors LEE, Jung Eun, KIM, Hyung Guk, LIM, Sang Min, LEE, Hyunjoo Jenny, SEONG, Jihye, KIM, Youngjae, KWAG, Rina, YEOM, Miyoung, CHOO, Hyunah
Format Patent
LanguageEnglish
French
Korean
Published 06.06.2019
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention relates to an arylpyrazolylpiperazine or arylpyrazolyldiazepane derivative represented by Structural Formula 1 and a pharmaceutically acceptable salt thereof. An arylpyrazolylpiperazine or arylpyrazolyldiazepane derivative and a pharmaceutically acceptable salt thereof according to the present invention exhibit excellent affinity for serotonin 5-HT7 receptor and can exert a therapeutic effect on a central nervous system disorder. La présente invention concerne un dérivé d'arylpyrazolylpipérazine ou d'arylpyrazolyldiazépane représenté par la formule de structure (1) et un sel pharmaceutiquement acceptable de celui-ci. Le dérivé d'arylpyrazolylpipérazine ou d'arylpyrazolyldiazépane et un sel pharmaceutiquement acceptable de celui-ci selon la présente invention présentent une excellente affinité pour le récepteur sérotoninergique 5-HT7 et peuvent exercer un effet thérapeutique sur un trouble du système nerveux central. 본 발명은 구조식 1로 표시되는 아릴피라졸릴피페라진 또는 아릴피라졸릴다이아제페인의 유도체 및 약제학적으로 허용 가능한 이의 염에 관한 것이다. 이에 따라, 본 발명의 아릴피라졸릴피페라진 또는 아릴피라졸릴다이아제페인의 유도체 및 약제학적으로 허용 가능한 이의 염은 5-HT7 세로토닌 수용체에 대하여 우수한 결합친화력을 나타내며, 중추신경계 질환 치료에 효과를 나타낼 수 있다.
Bibliography:Application Number: WO2018KR14838